Natco Pharma Approves Agro Chemical Demerger, Declares Dividend

Natco Pharma Limited reported consolidated revenue from operations of ₹4,078.3 crore and a consolidated net profit of ₹1,418.5 crore for the year ended March 31, 2026. This represents a 7.9% decrease in revenue and a 24.7% decline in net profit compared to FY25.

Reader Takeaway: Strategic demerger and dividend payout announced amidst a profit dip and past agro segment impairments.

What just happened

Natco Pharma's Board of Directors approved a scheme of arrangement to demerge its Agro Chemical business into a new wholly-owned subsidiary, NATCO Crop Health Sciences Limited. The company also declared a dividend of ₹5 per equity share for the financial year ended March 31, 2026. For the year ended March 31, 2026, the company posted consolidated revenue of ₹4,078.3 crore and a consolidated net profit of ₹1,418.5 crore.

A one-time deferred tax asset recognition of ₹115 crore due to the adoption of a new tax regime was included in the FY26 financial performance. The company's pharmaceuticals segment reported revenue of ₹3,940.1 crore and segment results of ₹1,547.3 crore, while the agro chemicals segment contributed ₹138.2 crore in revenue with segment results of ₹-19.8 crore.

Why this matters

The demerger aims to strategically realign the business, potentially allowing for focused growth and value unlocking for both the pharmaceutical and agro chemical segments. The dividend payout offers a direct return to shareholders. However, the reported decline in consolidated profit and revenue warrants attention.

The backstory

Earlier, on November 11, 2025, Natco Pharma acquired a 35.75% stake in South Africa's Adcock Ingram Holdings Limited for ₹1,991.2 crore, integrating it into its pharmaceuticals segment. The company also reported a historical impairment of ₹50 crore in its agro chemical segment in FY25, indicating prior operational challenges in that division.

What changes now

Shareholders can expect a clearer structure with the proposed demerger of the agro chemical business. The dividend will be distributed as approved. The acquisition of Adcock Ingram is expected to bolster the pharmaceuticals segment's international presence and contribution.

Risks to watch

The primary concern is the decline in consolidated profit and revenue for FY26. Investors should also monitor the operational performance and market reception of the demerged agro chemical entity and the successful integration and performance of Adcock Ingram.

Peer comparison

Natco Pharma operates in the pharmaceutical and agro chemical sectors. Its pharmaceutical peers include companies like Dr. Reddy's Laboratories, Sun Pharma, and Cipla, while agro chemical peers include UPL and Rallis India. The company's strategic moves, such as acquisitions and demergers, are key differentiators in a competitive landscape.

Context metrics (time-bound)

For the year ended March 31, 2026, consolidated revenue was ₹4,078.3 crore, down 7.9% from ₹4,429.5 crore in FY25. Consolidated net profit was ₹1,418.5 crore, a decrease of 24.7% from ₹1,883.4 crore in FY25. The company acquired a 35.75% stake in Adcock Ingram for ₹1,991.2 crore in November 2025.

What to track next

Investors will be keen to observe the progress of the agro chemical demerger, the performance of the acquired Adcock Ingram stake, and the company's ability to reverse the trend of declining revenue and profit in the upcoming financial periods.